These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 16595706)

  • 1. Human androgen receptor gene ligand-binding-domain mutations leading to disrupted interaction between the N- and C-terminal domains.
    Jääskeläinen J; Deeb A; Schwabe JW; Mongan NP; Martin H; Hughes IA
    J Mol Endocrinol; 2006 Apr; 36(2):361-8. PubMed ID: 16595706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural features discriminate androgen receptor N/C terminal and coactivator interactions.
    Askew EB; Minges JT; Hnat AT; Wilson EM
    Mol Cell Endocrinol; 2012 Jan; 348(2):403-10. PubMed ID: 21664945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An examination of how different mutations at arginine 855 of the androgen receptor result in different androgen insensitivity phenotypes.
    Elhaji YA; Wu JH; Gottlieb B; Beitel LK; Alvarado C; Batist G; Trifiro MA
    Mol Endocrinol; 2004 Aug; 18(8):1876-86. PubMed ID: 15118070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor.
    Doesburg P; Kuil CW; Berrevoets CA; Steketee K; Faber PW; Mulder E; Brinkmann AO; Trapman J
    Biochemistry; 1997 Feb; 36(5):1052-64. PubMed ID: 9033395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial androgen insensitivity with phenotypic variation caused by androgen receptor mutations that disrupt activation function 2 and the NH(2)- and carboxyl-terminal interaction.
    Quigley CA; Tan JA; He B; Zhou ZX; Mebarki F; Morel Y; Forest MG; Chatelain P; Ritzén EM; French FS; Wilson EM
    Mech Ageing Dev; 2004; 125(10-11):683-95. PubMed ID: 15541764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partial androgen insensitivity and correlations with the predicted three dimensional structure of the androgen receptor ligand-binding domain.
    Yong EL; Tut TG; Ghadessy FJ; Prins G; Ratnam SS
    Mol Cell Endocrinol; 1998 Feb; 137(1):41-50. PubMed ID: 9607727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for DNA-binding domain--ligand-binding domain communications in the androgen receptor.
    Helsen C; Dubois V; Verfaillie A; Young J; Trekels M; Vancraenenbroeck R; De Maeyer M; Claessens F
    Mol Cell Biol; 2012 Aug; 32(15):3033-43. PubMed ID: 22645304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human androgen receptor mutation disrupts ternary interactions between ligand, receptor domains, and the coactivator TIF2 (transcription intermediary factor 2).
    Lim J; Ghadessy FJ; Abdullah AA; Pinsky L; Trifiro M; Yong EL
    Mol Endocrinol; 2000 Aug; 14(8):1187-97. PubMed ID: 10935543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disrupted amino- and carboxyl-terminal interactions of the androgen receptor are linked to androgen insensitivity.
    Thompson J; Saatcioglu F; Jänne OA; Palvimo JJ
    Mol Endocrinol; 2001 Jun; 15(6):923-35. PubMed ID: 11376111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired helix 12 dynamics due to proline 892 substitutions in the androgen receptor are associated with complete androgen insensitivity.
    Elhaji YA; Stoica I; Dennis S; Purisima EO; Lumbroso R; Beitel LK; Trifiro MA
    Hum Mol Genet; 2006 Mar; 15(6):921-31. PubMed ID: 16449235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region.
    Wang Q; Lu J; Yong EL
    J Biol Chem; 2001 Mar; 276(10):7493-9. PubMed ID: 11102454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators.
    Ikonen T; Palvimo JJ; Jänne OA
    J Biol Chem; 1997 Nov; 272(47):29821-8. PubMed ID: 9368054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Domain interactions between coregulator ARA(70) and the androgen receptor (AR).
    Zhou ZX; He B; Hall SH; Wilson EM; French FS
    Mol Endocrinol; 2002 Feb; 16(2):287-300. PubMed ID: 11818501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription.
    Song LN; Herrell R; Byers S; Shah S; Wilson EM; Gelmann EP
    Mol Cell Biol; 2003 Mar; 23(5):1674-87. PubMed ID: 12588987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone.
    Askew EB; Gampe RT; Stanley TB; Faggart JL; Wilson EM
    J Biol Chem; 2007 Aug; 282(35):25801-16. PubMed ID: 17591767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor ligand-binding domain interaction and nuclear receptor specificity of FXXLF and LXXLL motifs as determined by L/F swapping.
    Dubbink HJ; Hersmus R; Pike AC; Molier M; Brinkmann AO; Jenster G; Trapman J
    Mol Endocrinol; 2006 Aug; 20(8):1742-55. PubMed ID: 16627595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.
    Ozers MS; Marks BD; Gowda K; Kupcho KR; Ervin KM; De Rosier T; Qadir N; Eliason HC; Riddle SM; Shekhani MS
    Biochemistry; 2007 Jan; 46(3):683-95. PubMed ID: 17223690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence that lack of ligand-binding domain correlates with nuclear distribution of unliganded human androgen receptor and loss of transactivation activity.
    Suzuki N; Imai A
    Gynecol Endocrinol; 2011 Nov; 27(11):940-3. PubMed ID: 21501000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosteric conversation in the androgen receptor ligand-binding domain surfaces.
    Grosdidier S; Carbó LR; Buzón V; Brooke G; Nguyen P; Baxter JD; Bevan C; Webb P; Estébanez-Perpiñá E; Fernández-Recio J
    Mol Endocrinol; 2012 Jul; 26(7):1078-90. PubMed ID: 22653923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions.
    Duff J; McEwan IJ
    Mol Endocrinol; 2005 Dec; 19(12):2943-54. PubMed ID: 16081517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.